

NEWS RELEASE

Contact: Bob Cardon, Dynatronics Corp.
800-874-6251, or 801-568-7000

Dynatronics Announces Successful Introduction of New Products at National Dealers' Meeting

Salt Lake City, Utah (July 6, 2005) – Dynatronics Corporation (NASDAQ: DYNT) introduced its lineup of new, innovative products at its national dealers' meeting held in Park City, Utah, on June 24th and 25th. Over 100 sales representatives from the United States and other countries participated in the two-day event. The new products include:

- The **Dynatron X3** light therapy device
- The **Dynatron Xp** light therapy pad
- The **Dynatron DX2** combination light therapy and traction device
- The **Dynatron T3 and T4** motorized therapy tables
- The **Dynatron Booster Box** which facilitates use of the new Xp pad by current Solaris users
- The **D880Plus** light probe, featuring higher power than the previous light probe
- The **D405** infrared and blue light probe
- The **iBox** iontophoresis device for delivering medication transdermally without needles

“Never in our history have we had such a broad range of new products ready to introduce,” said company president, Kelvyn H. Cullimore Jr. “We believe our ability to rapidly bring these products to market has been a strategic strength. It reinforces our reputation as an innovative, technological leader in our industry.”

During the fiscal year ended June 30, 2005, Dynatronics made the largest annual research and development investment in its history, continuing an R&D initiative launched over three years ago. “Our investment in R&D will again pay dividends with the introduction of these eight new products,” said Cullimore. “We believe these important innovations will boost sales and profits, just as the Solaris product line did two years ago. We also anticipate improved gross margins as a result of the new offerings.”

The new products herald a number of advances. For example, the Dynatron Xp is the first large, flexible light therapy pad for unattended therapy treatment.

“One of our initial goals is to capitalize on our installed base of several thousand Solaris units now in the field by introducing the new Dynatron Xp light pad and Booster Box,” said Larry K. Beardall, Dynatronics' executive vice president of marketing and sales. “The new light pad will transform the entire paradigm of how light therapy is delivered to patients because it can treat large areas of the body with a single, unattended application. Plus, this technology will broaden

our base of specialty products by helping us leverage light therapy into other treatment areas, such as decompression. We've also improved the user interface on several new devices by incorporating touch-screen technology."

Dynatronix plans to begin shipping the first of these new medical products within 60 days, and should begin shipping all new products before year's end.

"This was the best dealer meeting we've ever had," remarked Beardall. "The dealers came away very excited about the potential of the new products and technologies."

Dynatronix manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronix is available at www.dynatronix.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, FDA clearance of new products, growth in the physical medicine industry, competitive factors, availability of third-party component parts and products, inventory risks due to shifts in market demand, changes in product mix, market demand for the company's products and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-KSB for the year ended June 30, 2004, and its subsequent quarterly reports on Form 10-QSB.

###